Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Turkiye

被引:0
|
作者
Buyukyanbolu, Ecem [1 ,2 ]
Gill, Christian M. [2 ]
Genc, Leyla [1 ]
Karakus, Mehmet [3 ]
Comert, Fusun [4 ]
Otlu, Baris [5 ]
Aktas, Elif [1 ]
Nicolau, David P. [2 ]
机构
[1] Univ Hlth Sci, Hamidiye Etfal Training & Res Hosp, Dept Med Microbiol, Istanbul, Turkiye
[2] Hartford Hosp, Ctr Antiinfect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA
[3] Univ Hlth Sci, Dept Med Microbiol, Istanbul, Turkiye
[4] Bulent Ecevit Univ, Fac Med, Dept Med Microbiol, Zonguldak, Turkiye
[5] Inonu Univ, Fac Med, Dept Med Microbiol, Malatya, Turkiye
关键词
P; aeruginosa; Dose optimization; Cephalosporin; PK/PD; Carbapenem resistance; IN-VIVO EFFICACY; DOSING INTERVALS; THIGH-INFECTION; BETA-LACTAM; INFUSION; PHARMACODYNAMICS; PNEUMONITIS; MEROPENEM; IMIPENEM; OUTCOMES;
D O I
10.1007/s10096-024-04990-w
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Although CRPA may test susceptible to other beta-lactams such as ceftazidime (CAZ), cefepime (FEP), and piperacillin/tazobactam (TZP), reduced potency has been observed. We assessed the adequacy of EUCAST Susceptible (S) or Susceptible Increased Exposure (SIE)/(I) doses for CAZ, FEP, and TZP against CRPA clinical isolates. Methods CRPA isolates were collected from patients at three Turkish hospitals. CAZ, FEP, and TZP MICs were determined using broth microdilution. Monte Carlo simulations were performed to determine the probability of target attainment (PTA) for a free time above the MIC (fT > MIC) targets for various doses of each agent against isolates defined as susceptible. fT > MIC targets were 70% for CAZ or FEP and 50% for TZP. Cumulative fraction of response (CFR) was calculated. Optimal PTA and CFR was 90% target achievement. Results The percentages of isolates SIE/I to CAZ, FEP, and TZP were 49,8%, 47%, and 31,8% respectively. Reduced potency was noted with 54,1% of CAZ-S isolates having MICs of 4 or 8 mg/L. Of the FEP and TZP-S isolates, MICs at the breakpoint (8 and 16 mg/L, respectively) were the mode with 45,2 and 53,9% of isolates for each, respectively. At an MIC of 8 mg/L for CAZ, the EUCAST standard dose was insufficient (CFR of 85%). 3 h infusions of EUCAST SIE doses were required for 90% PTA at MIC of 8 mg/L and an optimized CFR of 100%. For FEP, the SIE dose of 2 g q8h 0.5 h infusion of was effective (CFR 96%), utilization of an extended 3 h infusion further optimized the PTA at 8 mg/L (CFR 99%). For TZP, the standard dose of 4.5 q6h administered as a 0.5 h infusion was inadequate (CFR 86%). A standard TZP dose with an extended infusion (4.5 g q8h over 4 h) and the SIE dose 4.5 g q6h 3 h infusion resulted in CFRs > 95%. Conclusion These data support the EUCAST SIE breakpoints for FEP and TZP. To optimize PTA at the SIE breakpoint for CAZ, prolonged infusion is required.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 50 条
  • [1] Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent
    Gill, Christian M.
    Nicolau, David P.
    CLINICAL THERAPEUTICS, 2023, 45 (01) : 72 - 77
  • [2] Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany
    Kresken, Michael
    Koerber-Irrgang, Barbara
    Korte-Berwanger, Miriam
    Pfennigwerth, Niels
    Gatermann, Soeren G.
    Seifert, Harald
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (06)
  • [3] In vitro Reducing Effect of Cloxacillin on Minimum Inhibitory Concentrations to Imipenem, Meropenem, Ceftazidime, and Cefepime in Carbapenem-resistant Pseudomonas aeruginosa Isolates
    Pahlavanzadeh, Farahnaz
    Kalantar-Neyestanaki, Davood
    Motamedifar, Mohammad
    Mansouri, Shahla
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 2020, 93 (01): : 29 - 34
  • [4] Activity of ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa
    Wi, Y. M.
    Greenwood-Quaintance, K. E.
    Ko, K. S.
    Kwon, K. T.
    Jung, S. -I.
    Kim, Y. -S.
    Kim, S. -W.
    Yeom, J. -S.
    Peck, K. R.
    Song, J. -H.
    Patel, R.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S124 - S125
  • [5] The activity of ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa
    Ito, Carmen Antonia Sanches
    Bail, Larissa
    Arend, Lavinia Nery Villa Stangler
    Nogueira, Keite da Silva
    Tuon, Felipe Francisco
    INFECTIOUS DISEASES, 2021, 53 (05) : 386 - 389
  • [6] Synergistic effect of polyethylenimine plus piperacillin/tazobactam on clinical Pseudomonas aeruginosa isolates resistant to piperacillin/tazobactam
    Bonfiglio, Giovanni
    ANNALS OF MICROBIOLOGY, 2006, 56 (04) : 345 - 348
  • [7] Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye
    Buyukyanbolu, Ecem
    Genc, Leyla
    Cyr, Elizabeth A.
    Karakus, Mehmet
    Comert, Fusun
    Otlu, Baris
    Aktas, Elif
    Nicolau, David P.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (09) : 1787 - 1794
  • [8] IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES
    Hosbul, Tugrul
    Aydogan, Canset Nur
    Kaya, Sinem
    Bedir, Rhan
    Ozcan, Hande
    Gumral, Ramazan
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2022, 85 (03): : 355 - 361
  • [9] Carbapenem-Resistant Pseudomonas aeruginosa
    Eraksoy, Haluk
    KLIMIK JOURNAL, 2014, 27 (02) : 37 - 37
  • [10] Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa
    Kakehi, Ayaka
    Hagiya, Hideharu
    Iio, Koji
    Fujimori, Takumi
    Okura, Mami
    Minabe, Hiroshi
    Yokoyama, Yukika
    Otsuka, Fumio
    Higashikage, Akihito
    NEW MICROBIOLOGICA, 2023, 46 (02): : 213 - 215